The arrival of a 750 mcg teriparatide injection in Australia has sparked considerable attention within the medical community. Currently, its access is restricted, primarily through specialist doctors and qualified centers. Revenue figures for this higher strength remain somewhat unavailable, but indications suggest a slow uptake due to the signific